Shunten International (Holdings) Limited Overview
Shunten International is a Hong Kong micro-cap that develops, manufactures, markets and distributes health and beauty supplements. It also runs a small and shrinking property investment portfolio. Its anchor franchise is "Royal Medic" (御藥堂), a traditional-Chinese-medicine-inspired supplement brand. The brand is promoted heavily on television and through long-standing celebrity ambassadors, and is sold through a dominant Hong Kong/Macau health-and-beauty retail chain (the single largest customer, about 51% of FY2026 revenue). Sales also come from about 60 in-store "special designated counters", the Hong Kong Brands and Products Expo, the group's own e-commerce site, and cross-border platforms such as Tmall. Gross margins are high (about 76–78%), but heavy rent, commission and advertising costs absorb them. The business is fully exposed to Hong Kong retail sentiment and inbound tourism. A leveraged property portfolio has produced HK$61.7M of cumulative fair-value losses over FY2024–FY2026. Since a September 2025 mandatory offer, Chairman Cheung Siu Fai's concert group has held majority control.
Company's own description
In the FY2026 final results announcement, the company describes itself as an investment holding company. Its group is principally engaged in Hong Kong in developing, manufacturing, selling, marketing and distributing health and beauty supplements and products, and in property investment. The FY2024 announcement had described the business more narrowly as "sale, marketing and distribution". Adding "development and manufacturing" in FY2026 reflects the company's emphasis on in-house formulation and its R&D centre.
Management describes two brand architectures:
Proprietary brands: are developed and managed by the group. The FY2026 list is 御藥堂 (Royal Medic), 中大中藥傳承 (Legend), 溶腩酵素 (MeltyEnz), 淨腸酵素 (CleansingEnz), 格斯圖 (La Gusto), Prof Health, HARUKA, 男鋼75 (Mr.
Private label: 康寶庫 ("Health Proof") is developed specifically for, and owned by, a well-known health-and-beauty retail chain in Hong Kong and Macau.
Business model and revenue model
| Dimension | Characterisation |
|---|---|
| Revenue type | About 97.7% product sales (health & beauty supplements), recognised at a point in time on delivery. About 2.3% rental income from investment properties under fixed-rent operating leases (FY2026). |
| Subscription / licensing | None disclosed. A loyalty scheme ("RM Club") awards points that expire every 31 March. |
| Principal vs agent | All product revenue is recognised as principal (FY2026 Note 4) |
| Returns | Some contracts carry return rights; refund liabilities were HK$1.4M at 31 Mar 2026 |
| New revenue line (FY2026) | Service income from using the group's promoter team to market traditional Chinese medicine products for industry peers. It is booked in "other income" and lifted that line to HK$3.1M from HK$0.9M. |
| Credit terms | 0–90 days to customers; 0–90 days from suppliers |
Value chain position
The group spans formulation and R&D (Royal Medic R&D Centre, Hong Kong Science Park), manufacturing (in-house, plus subcontracting cited as a component of cost of sales), brand marketing, and distribution and retail. Its retail presence runs through counters inside a third-party chain rather than a self-owned store network. Cost of sales covers raw and packaging materials, production staff and subcontracting costs. That cost base is small at HK$48.2M in FY2026, about 24% of revenue. The value capture problem lies downstream: counter rent (HK$34.1M), promoter commissions, advertising and celebrity endorsements, and administrative salaries absorb the gross margin.
Customer types and end-markets
Retail chain distributor (B2B2C): "Customer A" contributed HK$102.6M (51.2% of revenue) in FY2026. It had contributed HK$111.9M (54.6%) in FY2025, HK$137.4M (58.3%) in FY2024 and HK$160.9M (74.5%) in FY2023. The customer is not named in filings. The description (a renowned Hong Kong/Macau health-and-beauty chain that owns the "Health Proof" private label) is consistent with a market-leading pharmacy chain, but that identification is an unconfirmed inference.
Direct consumers (B2C): through special designated counters, which are counters inside the chain's stores staffed by group promoters, with rent calculated on gross counter sales. Also through the HK Brands and Products Expo, the own e-commerce platform, and stores on third-party and cross-border platforms.
End-markets: Hong Kong local consumers, Macau, and mainland Chinese visitors and cross-border online buyers. All product revenue is booked as Hong Kong-domiciled revenue (FY2024 Note 4).
Independent characterisation
Shunten is in practice a single-market, brand-led consumer health franchise that depends on one channel. It trades as a deep-value micro-cap whose balance sheet has been weighed down by property speculation. The supplement business generates positive segment profit, but that profit has collapsed from HK$69.6M (FY2023) to HK$8.9M (FY2026). Over the same period, revenue fell only from HK$215.9M to HK$195.7M. The cost structure is therefore sticky and largely fixed or variable-to-channel. The principal value drivers are Hong Kong tourist and resident retail spending, the terms of the dominant retail partner, and the success of a heavy new-product cadence.
Strategy
Stated strategic themes (FY2026 annual results, paraphrased)
-
Portfolio enrichment and accelerated R&D: launch innovative products and new brands that broaden functional benefits for health-conscious consumers (e.g. Cordyceps Cs-4, 淨肝健 2.0, the 御方正品 brand).
-
Celebrity-led marketing: continue the long partnership with Michelle Yim, and add Aimee Chan and 許博文 for 2026 launches across TV, social media and roadshows. The tagline is "為您健康把關" ("guarding your health").
-
Omni-channel optimisation: add special designated counters at selected locations, and upgrade third-party online stores and the own e-commerce platform.
-
Strict cost discipline: control raw-material procurement, logistics, advertising and operating expenses to protect margins.
-
Prudent property management: maintain occupancy and stable rental income; recycle capital when timing is right (Mid-Levels exit).
-
Capital-structure flexibility: AGM resolutions in September 2026 proposed an increase in authorised share capital and new articles, plus general mandates to issue and buy back shares. The specific purpose was not stated in the materials reviewed. It is an enabling step that could facilitate future equity issuance.
Initiatives in the last 24 months
| Date | Initiative | Type | Detail / target |
|---|---|---|---|
| Jun 2024 | Tmall flagship store | Channel / PRC expansion | Reach mainland consumers |
| Jun 2024 | New CRM system and RM Club member app | Digital | Data-driven marketing and product development |
| FY2025–FY2026 | New and upgraded SKUs (強胃健, 參睡紫靈芝, 一錠速眠, 速祛濕 upgrade) | Product | Revenue defence |
| FY2026 | Online stores on well-known e-commerce platforms | Channel | Digital customer acquisition |
| FY2026 | Promotion services for peers' TCM products | New revenue line | Monetise promoter team |
| FY2026 | Department restructuring; one-off retirement settlements | Cost / organisation | Targets not quantified |
| Jul–Oct 2025 | Mid-Levels residential disposal (HK$28.0M) | Capital recycling | Deleveraging and working capital |
| Apr 2026 | Cordyceps Cs-4 and 淨肝健 2.0 campaigns | Product / marketing | Multi-channel campaign |
| Jul 2026 | Authorised share capital increase; new articles | Corporate finance | Flexibility |
ESG commitments. An ESG report is included in each annual report.
Medium-term financial targets / guidance. None published. The company issues profit warnings and alerts under Listing Rule 13.09 but provides no forward guidance.
Products & Services
Pricing, detailed specifications and SKU counts are not disclosed in the HKEX filings reviewed. Product descriptions below draw only on filing disclosures. Functional descriptions inferred from product names are flagged as such.
Health & Beauty Supplements and Products segment
| Brand / product | Type | Description and positioning | Target customer | Launch / latest version | Source |
|---|---|---|---|---|---|
| 御藥堂 Royal Medic (master brand) | Proprietary | Flagship TCM-inspired health supplement brand. Spokespersons Michelle Yim (米雪, long-standing), Michael Miu (苗僑偉, FY2024), Aimee Chan (陳茵媺) and 許博文 "Johnny" (from Apr 2026). | Mass-market HK consumers, historically middle-aged and older; management seeks to attract younger buyers | Brand predates 2013 IPO | FY2024 & FY2026 MD&A |
| 御藥堂強胃健 | New SKU | Name suggests a digestive and stomach health supplement (functional description inferred) | Adults with digestive concerns | Launched FY2026 | FY2026 MD&A |
| 御藥堂參睡紫靈芝 | New SKU | Ginseng and purple lingzhi blend; name suggests a sleep aid (inferred) | Adults with sleep issues | Launched FY2026 | FY2026 MD&A |
| 御藥堂速祛濕 | Upgraded best-seller | Name suggests a "dampness-dispelling" TCM supplement (inferred) | TCM-oriented consumers | Upgraded version FY2026 | FY2026 MD&A |
| 御藥堂賦活蟲草 Cs-4 | New SKU | Cordyceps (Cs-4 strain) supplement; ambassador Aimee Chan | Energy and vitality segment | Launched after 31 Mar 2026 | FY2026 MD&A (Outlook) |
| 御藥堂淨肝健 2.0 | Upgraded SKU | Name suggests a liver-health supplement (inferred); ambassador 許博文 | Adults | Version 2.0 launched after 31 Mar 2026 | FY2026 MD&A (Outlook) |
| NMN product (Royal Medic range) | New category | Nicotinamide mononucleotide anti-ageing supplement; spokesperson Hins Cheung (張敬軒) | Ages 20–60 (management's stated fan-base reach) | Launched FY2024 | FY2024 MD&A |
| 中大中藥傳承 Legend | Proprietary | TCM heritage-positioned line (detail not disclosed) | — | — | FY2024/26 MD&A |
| 溶腩酵素 MeltyEnz | Proprietary | Enzyme product; name suggests body-shaping and weight management (inferred) | Beauty and slimming segment | — | FY2024/26 MD&A |
| 淨腸酵素 CleansingEnz | Proprietary | Enzyme product; name suggests digestive cleansing (inferred) | Beauty and wellness | — | FY2024/26 MD&A |
| 格斯圖 La Gusto | Proprietary | Detail not disclosed | — | — | FY2024/26 MD&A |
| HARUKA | Proprietary | Japanese-styled brand name; detail not disclosed | — | — | FY2024/26 MD&A |
| 男鋼75 Mr. 75 | Proprietary | Name suggests a men's health supplement (inferred) | Adult men | — | FY2024/26 MD&A |
| Prof Health | Proprietary | Added to brand list by FY2026; detail not disclosed | — | — | FY2026 MD&A |
| 御方正品 (incl. 一錠速眠) | Proprietary (new brand) | New brand. 一錠速眠 ("one-tablet fast sleep") launched FY2026; sleep positioning inferred from the name. | Sleep segment | FY2026 | FY2026 MD&A |
| 康寶庫 Health Proof | Private label | Developed for, and owned by, a renowned HK/Macau health-and-beauty retail chain | The chain's shoppers | — | FY2024/26 MD&A |
Services and channels within the segment
| Offering | Description | Year |
|---|---|---|
| Special designated counters | Group-staffed counters inside a chain distributor's stores, including at HK International Airport and cross-border points such as Lok Ma Chau MTR (reopened FY2024). 61 counters at 31 Mar 2024 (55 at 31 Mar 2023); FY2025 and FY2026 counts not disclosed in the announcements; expansion to "selected locations" planned. | Ongoing |
| Own e-commerce platform | Direct-to-consumer web store; marketing stepped up in FY2026 | Ongoing |
| Third-party e-commerce stores | Online stores opened on "well-known e-commerce platforms" (platforms not named) | FY2026 |
| Tmall flagship store | Cross-border store for mainland consumers | Jun 2024 |
| RM Club loyalty app and CRM | Points balance and redemption, customer data analytics | Jun 2024 |
| HK Brands and Products Expo | Annual trade-fair sales channel | Recurring |
| Promotion services for industry peers | Group promoter team markets peers' TCM products; booked as other income | FY2026 |
| Earlier: OEM, general administrative and management services; licence and trademark holding | Listed in third-party business descriptions | Historic / ongoing (n.d.) |
Property Investment segment
| Asset | Location | Use | Status |
|---|---|---|---|
| 5-storey tenement building, 127 Kweilin Street | Sham Shui Po, Kowloon | Commercial and residential lettings | Held; acquired via company acquisition 13 Mar 2023 |
| Industrial property | Kwai Chung, NT | Industrial letting | Held; reclassified from owner-occupied in FY2024 |
| Residential property | Mid-Levels, HK Island | Residential letting | Sold via subsidiary disposal for HK$28.0M, completed 16 Oct 2025 |
The investment property carrying value was HK$132.4M at 31 Mar 2026, down from HK$176.7M (FY2025) and HK$207.1M (FY2024). All of it is pledged for bank borrowings.
Financial Narrative
Basis. FY2023–FY2026 are taken from audited figures in the FY2024 and FY2026 final results announcements. FY2022 uses the originally reported continuing-operations figures from the FY2021/22 annual report (revenue HK$163.0M, re-presented to HK$155.6M in FY2023). Its operating income, EBITDA and pre-tax lines come from a TipRanks aggregation and are flagged as secondary-source. FY2021 revenue was HK$223.1M and the loss attributable HK$127.4M (FY2021/22 annual report).
Income statement
Notes:
-
D&A is PP&E depreciation plus right-of-use depreciation plus intangible amortisation, taken from segment notes.
-
EBITDA is analyst-computed as operating income plus D&A. It reconciles to the aggregator figures for FY2023–FY2025.
-
No dividend has been declared or paid in any year FY2023–FY2026.
Margins and growth
Revenue CAGR. FY2022–FY2026 is +5.3% p.a. on the as-reported FY2022 base, or +6.5% on the re-presented HK$155.6M base. FY2023–FY2026 is −2.5% p.a. FY2021–FY2026 is −2.1% p.a. (all analyst-computed).
Commentary. The income statement shows a post-COVID rebound followed by a reversal.
FY2022→FY2023: revenue rose 32.6%, helped by reopening and a HK$11.9M fair-value gain.
FY2024: the revenue peak was HK$235.6M, driven by border reopening, consumption vouchers, reopened airport and border counters, and advertising. Profit nonetheless almost vanished. Admin expenses rose 21.7%, mainly sales-linked counter rent, which nearly doubled from HK$16.9M to HK$32.7M. S&D rose 15.0% on promoter commissions, and a HK$15.0M fair-value loss swung the property line.
FY2025: revenue fell 13.0%. Management attributes this to weak local consumption, outbound spending by residents, and visitors shifting from shopping to experiential travel. The operating cost base did not flex: S&D was HK$53.1M and admin HK$102.0M. The adjusted result moved to a loss of HK$5.8M.
FY2026: the headline loss narrowed to HK$26.6M because the fair-value loss halved to HK$16.3M and finance costs fell 31.9%. The adjusted loss, however, widened to HK$10.3M. Staff costs rose to HK$80.2M with restructuring and retirement settlements, counter rent rose to HK$34.1M, and higher input costs trimmed gross margin by about 1.1 points to 75.9%.
Balance sheet
Notes:
- FY2022 borrowings include bank and other borrowings and overdrafts.
Short/long split: all bank borrowings are classified as current because of repayment-on-demand clauses. At 31 Mar 2026 they comprised HK$84.0M current and nil non-current, all secured on leasehold land and buildings (HK$6.9M) and investment properties (HK$132.4M). Unused facilities at 31 Mar 2026 were HK$10M of banking facilities plus a HK$15M shareholder loan facility (FY2025: HK$10M and HK$18M; FY2024: HK$40M banking).
Balance sheet commentary. The FY2024 jump in investment properties to HK$207.1M was mostly a reclassification of owner-occupied premises, which is why PP&E fell from HK$68.4M to HK$12.7M. It also included a HK$27.8M OCI revaluation surplus, so it was not new investment. Since then, HK$45.7M of fair-value losses and the HK$28.0M Mid-Levels disposal have cut the portfolio by 36%. The disposal proceeds mainly retired bank debt, which fell by HK$34.9M in FY2026. Equity has fallen 37% from the FY2024 peak. The going-concern note in FY2026 records net current liabilities of HK$50.2M against cash of HK$7.4M. It relies on operating cash flows, covenant compliance, the pledged properties, and the shareholder's undrawn HK$15M facility.
Cash flow
Capex proxies come from segment "other information" notes. There were no buybacks in FY2023–FY2026 ("neither the Company nor any subsidiary purchased, redeemed or sold listed securities"). Indirect evidence: net debt excluding leases fell HK$31.7M in FY2026. Of that, HK$28.0M came from the disposal, which implies only modest internally generated cash after interest and leases.
Ratios (analyst-computed unless stated)
Ratio commentary.
-
Liquidity is structurally thin: the current ratio has been about 0.5–0.6x for four years.
-
Leverage measured against cash earnings has deteriorated sharply. Excluding the property fair-value line, FY2026 EBITDA of about HK$6.5M did not cover finance costs plus lease payments by a comfortable margin.
-
The long cash conversion cycle (about 190–220 days) is driven by inventory. It is typical of a supplement maker carrying raw materials and finished goods, but it ties up roughly HK$22–26M.
-
Receivable days are healthy because the dominant customer pays within 60 days. Overdue balances did rise to HK$8.1M at 31 Mar 2026 from HK$3.4M.
Half-year trend
H1 FY2026 adjusted net loss was HK$6.3M, against an adjusted profit of HK$2.7M in H1 FY2025. The fair-value loss was HK$6.3M (H1 FY2025: HK$7.0M). Gearing was 101.3% at 30 Sep 2025. Sources: interim announcements (Nov 2023, Nov 2025) and Nov 2024 profit warning coverage.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Segment | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Health & beauty supplements revenue (HKD Mn) | 215.9 | 230.6 | 199.9 | 195.7 |
Property investment revenue (HKD Mn) | 0.2 | 5.0 | 5.1 | 4.6 |
Total revenue (HKD Mn) | 216.1 | 235.6 | 205.0 | 200.3 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment and Segment Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
H&B segment result (HKD Mn) | 69.6 | 52.1 | 20.1 | 8.9 |
Property segment result incl. FV change (HKD Mn) | 11.8 | -15.4 | -29.6 | -14.8 |
Property segment result excl. FV change (HKD Mn, analyst-computed) | -0.1 | -0.4 | 0.8 | 1.5 |
H&B segment margin (%) | 32.2 | 22.6 | 10.1 | 4.5 |
H&B revenue YoY growth (%) | — | 6.8 | -13.3 | -2.1 |
Property revenue YoY growth (%) | — | 2,318.4 | 2.5 | -10.2 |
H&B share of group revenue (%) | 99.9 | 97.9 | 97.5 | 97.7 |
Property share of group revenue (%) | 0.1 | 2.1 | 2.5 | 2.3 |
Unallocated corporate expenses (HKD Mn) | 32.9 | 29.6 | 21.5 | 20.7 |
Segment Assets & Liabilities
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
H&B segment assets (HKD Mn) | 157.0 | 110.5 | 94.7 | 80.1 |
Property segment assets (HKD Mn) | 136.9 | 208.4 | 178.0 | 134.1 |
Unallocated assets (HKD Mn) | 45.5 | 25.4 | 16.2 | 13.9 |
H&B segment liabilities (HKD Mn) | 23.7 | 16.5 | 49.6 | 29.7 |
Property segment liabilities (HKD Mn) | 81.5 | 76.2 | 46.9 | 44.1 |
Unallocated liabilities (HKD Mn) | 90.8 | 80.0 | 57.0 | 45.3 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (HKD Mn) | 163.0 | 216.1 | 235.6 | 205.0 | 200.3 |
Cost of sales (HKD Mn) | 50.4 | 49.8 | 51.4 | 47.1 | 48.2 |
Gross profit (HKD Mn) | 112.5 | 166.3 | 184.2 | 158.0 | 152.1 |
Other income, gains or losses (HKD Mn) | — | 3.9 | 1.6 | 0.9 | 3.1 |
Selling & distribution expenses (HKD Mn) | — | 47.4 | 54.5 | 53.1 | 53.4 |
Administrative expenses (HKD Mn) | — | 85.3 | 103.8 | 102.0 | 106.4 |
Fair value change of investment properties (HKD Mn) | — | 11.9 | -15.0 | -30.4 | -16.3 |
Operating income before finance costs (HKD Mn) | -28.8 | 48.7 | 12.4 | -26.4 | -21.2 |
Depreciation & amortisation (HKD Mn) | — | 6.5 | 9.1 | 11.8 | 11.5 |
EBITDA reported basis (HKD Mn) | -18.5 | 55.2 | 21.5 | -14.6 | -9.8 |
EBITDA excl. investment property FV change (HKD Mn) | — | 43.3 | 36.5 | 15.8 | 6.5 |
Finance costs (HKD Mn) | — | 5.0 | 7.8 | 6.9 | 4.7 |
Pre-tax income continuing (HKD Mn) | -41.6 | 43.8 | 4.6 | -33.4 | -25.9 |
Taxation (HKD Mn) | — | 2.6 | 4.1 | 2.9 | 0.7 |
Net income attributable to owners (HKD Mn) | -43.9 | 41.0 | 0.6 | -36.2 | -26.6 |
Adjusted net profit/(loss) company-defined (HKD Mn) | — | 24.8 | 15.6 | -5.8 | -10.3 |
Basic & diluted EPS (HK cents) | — | 1.32 | 0.02 | -1.17 | -0.85 |
Dividend per share (HK cents) | — | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 69.0 | 76.9 | 78.2 | 77.0 | 75.9 |
Operating margin (%) | -17.6 | 22.5 | 5.2 | -12.9 | -10.6 |
EBITDA margin reported (%) | -11.3 | 25.6 | 9.1 | -7.1 | -4.9 |
EBITDA margin excl. FV (%) | — | 20.0 | 15.5 | 7.7 | 3.3 |
Net margin (%) | -26.9 | 19.0 | 0.2 | -17.7 | -13.3 |
Revenue YoY growth (%) | -27.0 | 32.6 | 9.0 | -13.0 | -2.3 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (HKD Mn) | — | 339.4 | 344.3 | 288.9 | 228.0 |
Investment properties (HKD Mn) | — | 136.9 | 207.1 | 176.7 | 132.4 |
Property plant & equipment (HKD Mn) | — | 68.4 | 12.7 | 11.0 | 9.3 |
Intangible assets (HKD Mn) | — | 7.4 | 16.3 | 19.3 | 14.9 |
Goodwill (HKD Mn) | — | 0 | 0 | 0 | 0 |
Inventories (HKD Mn) | — | 23.8 | 25.9 | 24.9 | 22.2 |
Trade receivables net (HKD Mn) | — | 40.0 | 27.7 | 24.0 | 24.6 |
Cash & cash equivalents (HKD Mn) | 35.3 | 13.1 | 12.7 | 5.5 | 7.4 |
Bank & other borrowings (HKD Mn) | 119.0 | 79.7 | 111.0 | 119.0 | 84.0 |
Amount due to a shareholder (HKD Mn) | — | 79.9 | 25.9 | 0 | 5.0 |
Lease liabilities total (HKD Mn) | — | 6.8 | 11.2 | 10.0 | 4.8 |
Total borrowings incl. shareholder loan (HKD Mn) | — | 159.6 | 136.9 | 119.0 | 89.0 |
Net debt excl. leases (HKD Mn) | 83.7 | 146.5 | 124.2 | 113.4 | 81.7 |
Total liabilities (HKD Mn) | — | 196.0 | 172.7 | 153.6 | 119.1 |
Equity attributable to owners (HKD Mn) | — | 146.0 | 172.9 | 136.6 | 110.2 |
Total equity (HKD Mn) | — | 143.4 | 171.6 | 135.3 | 108.9 |
Net working capital (HKD Mn) | -65.8 | -94.9 | -79.5 | -75.4 | -50.2 |
Cash Flow
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Capex: additions to PP&E (HKD Mn) | 1.9 | 5.0 | 0.4 | 0.4 |
Additions to intangible assets (HKD Mn) | 5.5 | 10.0 | 6.8 | 0 |
Dividends paid (HKD Mn) | 0 | 0 | 0 | 0 |
Share buybacks (HKD Mn) | 0 | 0 | 0 | 0 |
Disposal proceeds (HKD Mn) | — | — | — | 28.0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
ROE on average owners' equity (%) | 28.1 | 0.4 | -23.4 | -21.5 |
ROA on year-end total assets (%) | 12.1 | 0.2 | -12.5 | -11.7 |
ROIC: EBIT×(1−16.5%) / (equity + net debt) (%) | 14.0 | 3.5 | -8.9 | -9.3 |
Current ratio (x) | 0.51 | 0.52 | 0.48 | 0.57 |
Gearing: total borrowings / equity, company-reported (%) | 111.3 | 79.8 | 87.9 | 81.8 |
Net debt / EBITDA excl. FV (x) | 3.4 | 3.4 | 7.2 | 12.6 |
Interest coverage EBIT / finance costs (x) | 9.8 | 1.6 | -3.8 | -4.6 |
Interest coverage excl. FV (x) | 7.4 | 3.5 | 0.6 | -1.1 |
Asset turnover on average assets (x) | — | 0.69 | 0.65 | 0.77 |
Days inventory outstanding (days) | 174.5 | 183.9 | 192.9 | 168.5 |
Days sales outstanding (days) | 67.6 | 42.8 | 42.7 | 44.9 |
Days payables outstanding (days) | 22.3 | 16.7 | 29.9 | 20.5 |
Cash conversion cycle (days) | 219.8 | 210.0 | 205.7 | 192.9 |
Income Statement
| Metric | H1 FY2023 | H1 FY2024 | H1 FY2025 | H1 FY2026 |
|---|---|---|---|---|
Revenue (HKD Mn) | 112.3 | 128.0 | 103.0 | 102.1 |
H&B revenue (HKD Mn) | — | — | 100.2 | 99.4 |
Gross profit (HKD Mn) | 86.1 | 98.2 | 79.7 | 77.3 |
Profit/(loss) attributable (HKD Mn) | 18.7 | 10.8 | -4.3 | -12.6 |
Revenue by Region and Region Margins & Growth (%)
| Region | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Hong Kong revenue as reported (HKD Mn) | 216.1 | 235.6 | 205.0 | 200.3 |
Hong Kong YoY growth (%) | — | 9.0 | -13.0 | -2.3 |
Segment × Geography Details
| Segment × geography | FY2026 (HKD Mn) | Basis |
|---|---|---|
H&B, Hong Kong (incl. any Macau/PRC flows) | 195.7 | All booked in HK |
Property, Hong Kong | 4.6 | All properties in HK |
Valuation Snapshot
| Metric | Value | Source / basis |
|---|---|---|
Share price, early–mid Jul 2026 | HK$0.027–0.028 | etnet quotes (3, 16, 17 Jul 2026) |
Share price, 27 Dec 2024 | HK$0.032 | Moomoo snapshot (market cap HK$99.45M) |
Implied MGO acceptance value | ≈HK$0.024 per share | HK$1.3M ÷ 53.888M shares (analyst-derived) |
Market cap at HK$0.028 | ≈HK$87.0M | 3,107.893M shares |
Enterprise value | ≈HK$173M | Market cap + borrowings HK$84.0M + shareholder loan HK$5.0M + leases HK$4.8M − cash HK$7.4M (31 Mar 2026) |
Multiple (at HK$0.028, FY2026 basis) | Value | — |
P/E (x) | n.m. (loss-making) | — |
EV/EBITDA reported (x) | n.m. (negative) | — |
EV/EBITDA excl. FV (x) | ≈26.6 | — |
EV/Sales (x) | ≈0.86 | — |
P/B on owners' equity HK$110.2M (x) | ≈0.79 | — |
Capital Markets
| Item | Detail |
|---|---|
Analyst consensus | No sell-side coverage identified |
Dividend history | Nil for FY2023, FY2024, FY2025 and FY2026; no interim dividend H1 FY2026 |
Dividend policy | Capital management statement: balance via dividends, issues and debt "as appropriate". No formal payout policy identified. |
Buybacks | General repurchase mandate sought at AGMs; no repurchases FY2023–FY2026 |
Credit ratings | None (Moody's / S&P / Fitch: not rated) |
Debt maturity profile | All bank borrowings (HK$84.0M) classified current due to repayment-on-demand clauses |
Unused facilities (31 Mar 2026) | HK$10M bank; HK$15M shareholder loan facility |
Pledged assets | Investment properties HK$132.4M; leasehold land and buildings HK$6.9M |
Liquidity | Average daily volume about 1.8–8.2M shares around the 2025 offer (TipRanks snapshots); very low value traded |
Analyst Conclusions
Management guidance
No quantitative guidance is given. The FY2026 outlook expects a still-challenging HK retail environment because of geopolitical tensions, uncertainty, changing consumption patterns and competition. Management's priorities are faster R&D and new brands, celebrity-led campaigns from April 2026, more counters, upgraded online stores, strict cost control, and a cautious approach to property with an occupancy focus. Consensus: none available.
Bull case
-
Cost reset plus product cycle: FY2026 absorbed one-off restructuring and retirement settlements and launch-heavy marketing. If these do not recur, gross margin holds at about 76%, and the Cs-4 and 淨肝健 2.0 launches stabilise H&B revenue at about HK$195–200M, then segment profit could recover toward the FY2025 level of HK$20.1M.
-
Deleveraging and asset backing: gearing fell from 111.3% (FY2023) to 81.8% (FY2026). The stock trades at about 0.79x book, and HK$132.4M of property remains available to recycle.
-
Control consolidation: the controller now holds about 50.5% and has added an investment-management executive director. This could lead to strategic actions such as restructuring, new capital or business injection, or a privatisation attempt.
Bear case
-
Structural margin erosion: adjusted results moved from +HK$24.8M (FY2023) to −HK$10.3M (FY2026). Counter rent (HK$34.1M) and staff costs (HK$80.2M) both rose in a year when revenue fell.
-
Liquidity fragility: HK$7.4M of cash, HK$84.0M of on-demand debt and HK$50.2M of net current liabilities leave the company dependent on lender forbearance and shareholder support.
-
Dilution and concentration: the July 2026 authorised-capital increase opens room for share issuance near HK$0.03 per share. Meanwhile, half of revenue depends on one retailer's goodwill.
Catalysts and monitorables (next 12 months)
Late Nov 2026: H1 FY2027 interim results. Watch the early sales impact of the Cs-4 and 淨肝健 2.0 launches, S&D intensity, and any profit warning issued about two weeks earlier.
Ongoing: any share issuance, placing or rights issue using the enlarged authorised capital.
Ongoing: property revaluations at Sept 2026 and Mar 2027, and any further asset disposals.
Ongoing: bank facility renewals and the use of the shareholder loan facility.
Ongoing: Customer A revenue share, counter count and counter rent trajectory.
Ongoing: board and management changes after the change of control, and any strategic announcements by Leading Virtue.
June 2027: FY2027 final results.
Analyst verdict
Shunten is a branded consumer-health franchise held back by its own cost structure and a speculative property detour. The core facts are stark. Gross margin has stayed in a tight 75.9–78.2% band for four years, so the product economics are intact. Yet H&B segment profit has fallen from HK$69.6M to HK$8.9M. The leak sits below gross profit, in sales-linked counter rent, promoter commissions, celebrity advertising and a HK$106M administrative base that does not flex when Hong Kong retail softens. Meanwhile, the property book has cost shareholders HK$61.7M in fair-value losses in three years and consumed balance-sheet capacity. The HK$28M Mid-Levels sale was the right move, but it was reactive.
The balance sheet is the binding constraint. Cash of HK$7.4M against HK$84.0M of on-demand bank debt means the company runs on lender confidence and a HK$15M shareholder line. That makes the September 2025 change of control and the July 2026 authorised-capital increase the most important developments for minority holders. They point to either fresh capital or a broader corporate action. Investors should treat the stock as an event-driven special situation rather than an operating compounder.
On valuation, the shares trade at roughly 0.8x book and 0.9x sales. That is cheap only if book value, which is largely Hong Kong secondary property, holds and the supplement business returns to positive adjusted earnings. Neither condition has yet been met. For the core business to turn, revenue needs to stabilise around HK$200M while counter rent and staffing are held flat. On FY2026 numbers, that would add roughly HK$10M of operating leverage. Until the interim results show evidence of this, the risks remain concentrated: one dominant customer, one market, and on-demand debt. The overall assessment is speculative and neutral-to-negative, with upside tied mainly to corporate action rather than operations. Key watchpoints are the November 2026 interims and any capital-raising announcement.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure / notes | Committees |
|---|---|---|---|
CHEUNG Siu Fai (張少輝) | Chairman and Executive Director | Signs all announcements since at least FY2023. Concert party with offeror Leading Virtue. Born 1970 (market data profile). | — |
| — | Executive Director | Appointed April 2026. A responsible officer of an asset manager (黑馬資本). | — |
SO Tsz Kwan (蘇芷君) | Non-Executive Director | Chaired the 3 Sep 2025 AGM in the Chairman's absence | — |
LEUNG Winson Kwan Yau (梁鈞滺) | Independent NED | Audit Committee Chairman | Audit (Chair) |
DONG Jian Mei (董建美) | Independent NED | On board since at least FY2024 | Audit |
| — | Independent NED | — | Audit |
Executive Leadership Team
| Name | Title | Year of birth |
|---|---|---|
Yeung Wai Lok | Chief Executive Officer | 1969 |
Wong Chak Man | Chief Financial Officer | 1982 |
Cheng Tze Kit | Group Chief Investment Officer | 1956 |
Yan Tat Ming | COO, Health, Beauty Supplements & Products | 1964 |
Lee Chi Hang | Chief Legal Adviser, H&B segments | 1964 |
Tsang Chi Wai | Chief Compliance Officer | 1964 |
Chong Siu Yu | Sales Director | 1974 |
Wong Suet Yin | Marketing Director | 1981 |
Yuen Yee Han | Administration Controller | 1961 |
Chan Yuk Chi | Company Secretary | — |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
31 Aug 2022 | INED Leung Man Loon departs | Board refresh |
Between Jun 2024 and Nov 2025 | INED Liu Ying Shun replaced by 林植信 | — |
3 Sep 2025 | Chairman absent from AGM; NED So Tsz Kwan presides | CG Code deviation F.1.3 |
Apr 2026 | 周華鴻 appointed Executive Director | First new executive director after the change of control |
Major Shareholders
| Holder | Shares | % of issued | Source |
|---|---|---|---|
Leading Virtue Holdings Ltd + concert parties (incl. Cheung Siu Fai) | 1,554,534,033 | 50.02% | Joint announcement, 20 Oct 2025 (includes 38.0M acceptances) |
Same group after final close (analyst-derived) | ≈1,570,422,033 | ≈50.53% | Adds the further 15.888M acceptances to the 4 Nov 2025 close of 53.888M total |
Public float | ≈1,537M | ≈49.5% | Derived |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Positioning vs Shunten |
|---|---|---|
Eu Yan Sang (private; delisted from SGX) | TCM supplements and retail | Much larger heritage TCM brand with its own store network |
Wai Yuen Tong Medicine (HKEX: 0897) | TCM products and supplements | Listed HK TCM peer with own retail |
PuraPharm (HKEX: 1498, "Nong's") | Concentrated Chinese medicine granules, supplements | Clinical/TCM orientation; larger |
Vita Green (private) | HK health supplements (lingzhi, cordyceps) | Direct overlap in lingzhi and cordyceps; strong own counters |
Hin Sang Group (HKEX: 6893) | Health and beauty products, HK/PRC | Listed micro-cap peer |
H&H International / Swisse (HKEX: 1112) | Adult nutrition and supplements | Global brand scale; cross-border e-commerce leader |
By-health (SZSE: 300146) | Vitamins and supplements, PRC | Mainland scale player relevant to cross-border ambitions |
Blackmores (Kirin) | Supplements in HK pharmacy chains | International brand competing for shelf space |
Pharmacy-chain private labels | OTC and supplements | Shelf competition; Shunten also supplies one ("Health Proof") |
Direct sellers (e.g. Herbalife, Amway Nutrilite, Infinitus) | Supplements | Different channel; overlapping consumers |
Competitor Detail
| Metric | Shunten FY2026 |
|---|---|
Revenue (HKD Mn) | 200.3 |
Revenue growth (%) | -2.3 |
Gross margin (%) | 75.9 |
Net margin (%) | -13.3 |



